Open Nav

Please submit your session questions in advance at

Mirum Pharmaceuticals

Mirum is a clinical stage company focused on difficult to treat liver diseases. Mirum's lead program, maralixibat, is planned to initiate Phase 3 in Alagille Syndrome and progressive familial intrahepatic cholestasis (PFIC) in 2019.

  • Date:Monday, February 11
  • Time:3:15 PM - 3:30 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23464
  • Goal for Presentation:Awareness of newly launched company and programs
  • Company
  • Company HQ City:Menlo Park
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:120,000,000
  • Size of Last Investment Round:120,000,000
  • CEO/Top Company Official:Mike Grey
  • Year Founded:2018
  • Main Therapeutic Focus:Gastrointestinal
  • Lead Product in Development:maralixibat
  • Development Phase of Primary Product:Phase III
Christopher Peetz
Mirum Pharmaceuticals, Inc.